Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAT | P00750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698960 | 0.80 | KDM4E (0.66) | KDM4EMYCMAPTGAAALDH1A1 | |
| SCHEMBL19705660 | 0.76 | GAA (0.34) | MAPTGAA | |
| SCHEMBL22674780 | 0.76 | GAA (0.34) | MAPTGAA | |
| SCHEMBL25360449 | 0.76 | KDM4E (0.46) | KDM4EMYCMAPTGAAALDH1A1 | |
| SCHEMBL2379171 | 0.76 | KDM4E (0.46) | KDM4EMYCMAPTGAAALDH1A1 | |
| SCHEMBL31481672 | 0.76 | KDM4E (0.46) | KDM4EMYCMAPTGAAALDH1A1 | |
| SCHEMBL348577 | 0.75 | MAPT (0.58) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL6560116 | 0.73 | MAPT (0.55) | KDM4EMAPTGAAALDH1A1TSHR | |
| SCHEMBL19705808 | 0.72 | KDM4E (0.41) | KDM4EMAPTALDH1A1TSHRMAPK1 | |
| SCHEMBL25170294 | 0.72 | KDM4E (0.42) | KDM4EMYCMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200360383-A1 | Quinazoline Compounds | GILEAD SCIENCES, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10548898-B2 | Quinazoline compounds | GILEAD SCIENCES INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190134035-A1 | Quinazoline Compounds | GILEAD SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10206926-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170354656-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2017-12-14 | — | — | US | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134035-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | KDM4E 4154/4885MYC 3345/4885MAPT 3/4885 |
| US-10206926-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | KDM4E 4154/4885MYC 3345/4885MAPT 3/4885 |
| US-20200360383-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | KDM4E 4154/4885MYC 3345/4885MAPT 3/4885 |
| US-10548898-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | KDM4E 4154/4885MYC 3345/4885MAPT 3/4885 |
| US-20170354656-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | KDM4E 4154/4885MYC 3345/4885MAPT 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.